Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 7/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748544 | 0.90 | HTR1A (0.50) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL30483753 | 0.89 | HTR1A (0.67) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL25282377 | 0.89 | HTR1A (0.67) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL25748355 | 0.85 | HTR6 (0.48) | HTR1AHTR6HTR2ACYP1A2CYP3A4 | |
| SCHEMBL25748542 | 0.85 | HTR1A (0.51) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL30483731 | 0.85 | HTR1A (0.51) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL30483765 | 0.83 | HTR1A (0.49) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL25424381 | 0.83 | HTR1A (0.49) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL25423594 | 0.82 | HTR2A (0.58) | HTR1AHTR6HTR2AHTR2CCYP1A2 | |
| SCHEMBL31077738 | 0.82 | HTR2A (0.58) | HTR1AHTR6HTR2AHTR2CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| EP-4452937-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | HTR1A 185/4885HTR6 54/4885HTR2A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.